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Abstract
Introduction: There has been renewed interest in mushroom medicinal properties. We studied
cholesterol lowering properties of Ganoderma lucidum (Gl), a renowned medicinal species.
Results:  Organic fractions containing oxygenated lanosterol derivatives inhibited cholesterol
synthesis in T9A4 hepatocytes. In hamsters, 5% Gl  did not effect LDL; but decreased total
cholesterol (TC) 9.8%, and HDL 11.2%. Gl (2.5 and 5%) had effects on several fecal neutral sterols
and bile acids. Both Gl doses reduced hepatic microsomal ex-vivo HMG-CoA reductase activity. In
minipigs, 2.5 Gl decreased TC, LDL- and HDL cholesterol 20, 27, and 18%, respectively (P < 0.05);
increased fecal cholestanol and coprostanol; and decreased cholate.
Conclusions:  Overall,  Gl  has potential to reduce LDL cholesterol in vivo through various
mechanisms. Next steps are to: fully characterize bioactive components in lipid soluble/insoluble
fractions; evaluate bioactivity of isolated fractions; and examine human cholesterol lowering
properties. Innovative new cholesterol-lowering foods and medicines containing Gl are envisioned.
Background
In Kampo Chinese folk medicine, mushrooms have been
known to have medicinal properties since AD1200 [1].
In recent years, there has been interest in the cholesterol
lowering properties of mushrooms, including Ganoderma
lucidum  (Reishi-, Longevity-, or Phantom mushrooms,
Biladi Top, Young-zhi, The King Of Herbs, Ling Zhi in
Chinese, Saru-no-koshikake and Mannendake in Japa-
nese) [2,3], Pleurotus ostreatus (Oyster mushroom) [4-8],
Volvariella volvacea (Straw mushroom) [9], Agaricus bis-
porus (champignon) [10], Agaricus campestris [11], Auricu-
laria auricula (Tree-ear),  Tremella fuciformis (White-jelly
leaf) [12,13], Grifola frondosa (Maitake mushroom)
[14,15], Lentinus erodes (Shiitake) and isolated fractions
[14,16], and Polyporus confluens (Ningyotake) [17]. In an
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earlier work, Kaneda and Tokuda [18] studied cholesterol
lowering properties of ether-, water- and ethanol extracts
from caps and stems from Lentinus edodes, Auricularia pol-
ytricha (Jews-ear), Flammulina velutipes, and Agaricus bis-
porus. The majority of these studies were performed in rats.
The cholesterol lowering properties of Cordyceps sinensis
were studied in humans [19].
Our focus is Gl, an important medicinal fungus belonging
to the Ganodermataceae family that has been studied for
its many interesting health promoting properties, includ-
ing anti-tumor, anti-inflammatory, and anti-platelet
aggregation [20-27]http://kyotan.com/lectures/lectures.
Indeed, entire books, symposiums, organizations (e.g.,
the  Ganoderma  International Research Institute, New
York) and therapies have been devoted to Gl. As further
testament to its importance, in ancient Chinese times, a
Reishi Goddess (Reishi senshi) was even worshipped to
bestow health, life and eternal youth.
As described, Gl has been occasionally studied for its cho-
lesterol lowering- and hypotensive properties in the rat [2]
and rabbit [28], but not in more physiological cholesterol
models [29] such as minipigs. Gl can supposedly lower
cholesterol in humans, but the work was not peer-
reviewed nor adequately described [24]http://www.gano
therapyusa.com/DXN/docs/whatis.htm.
Like humans, minipigs are omnivours, and their lipid and
steroid metabolism, and digestive and cardiovascular
physiology closely resembles that of humans [30-32];
whereas in contrast to humans, rodents carry most of the
cholesterol in HDL fractions unless they are fed high satu-
rated fat and cholesterol rich diets, which has the effect of
shutting down LDL receptors [29].
The components in Gl that may lower cholesterol are not
known, but may include ganoderan-type glucans
[22,33,34], hetero-β-glucans, glucan-protein complexes
(xyloglucans, uronic acid-β-glucans), other fibers, lectins
[25], terpenoid triterpenes [35-38], ergostane sterols [39],
and highly oxygenated ganoderic acid-type, lanostanoid
triterpenes [38-42]. Gl fibrous components could affect
cholesterol absorption and bile acid recycling, whereas
lipophilic components could affect cholesterol synthesis.
Gl may affect cholesterol synthesis at the committed 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMG-
CoA reductase) rate-limiting step; or at the latter lanos-
terol 14α-methyl demethylase:cytochrome P-450
demethylase (P-45014DM) step [43,44], catalyzing the
rate limiting step in lanosterol-cholesterol conversion. In
non-Gl mushroom species, inhibition of squalene syn-
thetase by zaragozic acid fungal metabolites has also been
reported in primates [45].
Herein, we tested the effects of Gl on cholesterol metabo-
lism in hepatic T9A4 human cells, a hamster small animal
model, and a minipig larger animal model having differ-
ent lipoprotein cholesterol distribution than the hamster
model. Animal models were fed cholesterol-containing
diets described in Tables 1, 2.
Results
Active components in Gl and in vitro activity
Organic and aqueous Gl phases did not contain HPLC-
detectable lovastatin. The organic extracted phase strongly
Table 1: Proximate analysis of Nafag 924 test diets for hamsters1
Weight %
Component Control 2.5% Gl 5.0% Gl
Carbohydrate (by difference) 31.8 31.0 30.3
Starch 23.6 23.0 22.5
Crude Protein 15.6 15.2 14.8
Water 8.0 7.8 7.6
Crude fat 4.4 4.3 4.2
Ash 4.7 4.6 4.5
Crude fiber 3.5 3.4 3.3
Essential amino acids 3.4 3.3 3.2
Gl extract 0.0 2.5 5.0
Vitamin mix (includes choline) 2.4 2.3 2.3
Minerals (Ca, P, Mg, K, Na) 2.3 2.2 2.2
Trace elements 0.3 0.3 0.3
1Nafag 924 hamster complete diet was from Eberle Nafag AG, Gossau, Switzerland. The detailed ingredients in the diet are not known. 
Metabolizable energy was estimated to be 3111 kcal/kg diet. The lovastatin diet was identical to the control diet, but contained 2 mg/100 g diet 
lovastatin. Gl, G. lucidum.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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inhibited cholesterol biosynthesis (ID50 = 1.3 µg/mL, rel-
ative to 0.4 for lovastatin), while the aqueous phase was
ineffective (ID50 > 330). Various highly oxygenated lanos-
tanoid triterpenes, and 32-methyl- and 26-oxo sterols
were found in the organic phase, and likely contributed to
inhibition of cholesterol synthesis. A 20% EtOAc/hexane
fraction contained ganoderal A; and a 50% EtOAc/hexane
contained ganoderols-A and B, and Y ganoderic acid.
Body and organ weights, and food intake of hamsters
Body weights ranged from 68.7–70.8 and 83.2–86.4 g for
the experimental groups on D1 and D18, respectively,
without significant differences relative to control, on D1,
D18, or D18 minus D1. D18 liver and cecum relative
weights (g organ/100 g body wt) were 2.77–2.84 and
0.52–0.56 for the various groups, respectively, without
significant differences relative to control. Daily food
intake was 7.1–7.8 g food/d averaged over D1-16; there
were no significant differences relative to control.
Cholesterol and triacylglycerol in hamsters
Starting D1 TC levels did not differ among the groups,
whereas there were differences in D1 TAG (Table 3). Gl at
2.5 and 5.0% reduced D18 TAG (likely due to D1 TAG dif-
ferential starting values). Gl at 2.5% did not reduce D18
TC, LDL or HDL. With 5.0% Gl, there was a statistical
trend (P < 0.10) to reduce TC and HDL; LDL was not
affected. Similarly to the higher dose of Gl, lovastatin
decreased D18 TC and HDL, but not LDL. LDL/HDL ratio
was not statistically significantly different for any dietary
treatments relative to control.
Fecal bile acids and neutral sterols in hamsters
Gl (2.5%) increased fecal total bile acids and chenodeox-
ycholate (Table 4). Both Gl doses increased coprostanol 3-
one, whereas, 5% Gl  decreased cholestanol. Lovastatin
had no significant effects on bile acids or neutral sterols
examined.
Ex vivo hepatic HMG-CoA reductase activity in hamsters
Lovastatin did not affect de-phosphorylated activity, and
phosphorylated activity not examined (Table 5). In
absence of NaF (inhibitor of phosphatase) and in pres-
ence of 2.5 and 5 % Gl, 3-hydroxy-3-methylglutaryl-CoA
reductase activity in hamster hepatic microsomes (pmol/
min/g liver) was reduced 2.1- and and 1.5 fold, respec-
tively, relative to the control. In presence of NaF, 2.5%
and 5% Gl reduced HMG-CoA reductase 3.5- and 1.9-
fold, respectively, relative to control.
Table 2: Ingredients in test diets for minipigs1
Component (g/100 g diet, as fed basis) Weight % Control or 2.5% Gl
Corn (to 100%) 26.6
Wheat shorts 29.8
Pork fat2 9.0
Soy meal (44%; contains soy protein) 8.5
Bakery by products 8.5
Unsalted, melted butter3 4.5
Amino acid mix4 3.4
Mineral mix5 2.8
Cellulose6 (control) or Gl7 2.5
Canola (rapeseed) meal 2.5
Poultry meal 1.7
Cholesterol8 0.1
Vitamin mix (includes choline)9 0.1
Trace element mix10 0.02
1Diets were custom prepared by Kliba (Kaiseraugst, Switzerland) as a fat and cholesterol enriched diet 2604. Unless indicated otherwise, stocks 
were from Kliba. Proximate analysis of minipig test diets (wt%) was: carbohydrate as nitrogen free extract 46.6, crude protein 15.9, water 11.1, 
crude fat 16.8, ash (including vitamins) 5.1, and crude fiber 4.6. Total- and digestible energy of the diet were estimated to be 3985 and 3776 kcal/kg 
diet, respectively. 2Centravo Schweinefett B 90, Centravo AG, Zurich, Switzerland. Contained 98% fat, 5% free fatty acids, 9% polyunsaturated fatty 
acids, protected with antioxidants. 3Migros Genossenschafts-Bund SA, Zurich, Switzerland. 82% fat, 0.5% protein, 0.5% carbohydrate. 4Per 100 g 
diet, contained 1.06% arginine, 0.75% lysine, 0.26% methionine, 0.56% methionine + cystine, 0.20% tryptophan, and 0.57% threonine [78]. 5Per 100 
g diet, contained 0.80% calcium, 0.70% phosphorus, 0.19% sodium, 0.63% potassium, 0.20% magnesium, and 0.26% chloride. 6Vitacel LC 200 
Cellulose, J. Rettenmaier & Söhne (JRS), GMBH + Co, Rosenberg, Holzmühle 1, Germany. 0.3% sulfate ash, pH 5.0–7.5, 300 µM fiber length. 
7Champitec, Payerne, Switzerland. Prepared as described in the text. Pigs that did not receive the Gl extract, received the control diet plus 80 mg 
lovastatin/pig/d in half an apple. 8Fluka 26740, Fluka Holding AG, Buchs, Switzerland. 97% pure. 9Roche Vitamins Ltd, Basel, Switzerland. In mg/100 g 
diet, contained 0.4 vitamin A (800 IU), 2.0 vitamin D3 (80 IU), 10.5 vitamin E, 0.3 vitamin K3, 1.2 vitamin B1, 0.8 vitamin B2, 3.0 nicotinic acid, 2.0 
pantothenic acid, 0.1 folic acid, 0.7 vitamin B6, 0.0034 vitamin B12, 0.02 biotin, 65.1 choline, and 2.0 vitamin C. 10In mg/100 g diet, contained 1.1 
copper (mg/kg), 7.6 zinc, 11.0 iron, 0.05 iodine, 5.0 manganese, and 0.03 selenium. Gl, G. lucidum.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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Fractional cholesterol synthesis rate in hamsters
In hamsters, 24 h FSR values (Atom% enrichment D17-
18) were 1.68 ± 0.20, 1.91 ± 0.16, 1.75 ± 0.36, and 2.29 ±
0.05 (mean of n = 6, ± 1 SEM) for control, lovastatin,
2.5%-, and 5% Gl, respectively. Values were not statisti-
cally significantly different from control.
Body weights of minipigs
Minipig body weights increased equivalently with Gl and
lovastatin from 19.0–26.9 kg over D1-28. Similar weights
per age were previously reported for experimentally-fed
Göttingen minipigs [46].
Cholesterol and triacylglycerol in minipigs
The experimental diet increased TC 27–30% from D1-14
(Table 6). In the Gl-fed group, TC significantly decreased
12.5% from D14-21, but not further from D21-29; the
decrease in TC from D14-29 was 20% (P < 0.01). Lovasta-
tin did not significantly decrease TC during D14-21 (P >
0.13), D21-29, nor D14-29; but TC did decrease >10% in
two pigs from D14-21.
Table 3: Plasma cholesterol and triacylglycerol in hamsters treated with G. lucidum and lovastatin (mmol/L)
Group TC TC TAG TAG VLDL LDL HDL LDL/HDL
D1 D18 D1 D18 D18 D18 D18 D18
Control 3.57 3.48 1.10 1.08 0.22 0.51 2.75 0.19
Lovastatin 3.39 3.16a 1.07 0.98 0.18a* 0.48 2.50a 0.19
Gl (2.5%) 3.46 3.40 0.64a 0.90a 0.18 0.53 2.69 0.20
Gl (5%) 3.34 3.14a* 0.89a*0 . 9 2 a 0.20 0.49 2.44a* 0.20
TC, total cholesterol; TAG, triacylglycerol; VLDL, LDL, HDL, very low-, low-, and high-density lipoproteins; D, day; LOVA, 20 mg/kg diet. Values 
represent mean of 6 animals. aSignificantly different from the control (P < 0.05 or *P < 0.10), students, unpaired, 1-tailed,t-test, equal variances.
Table 4: Fecal bile acids and neutral sterols in hamsters treated with G. lucidum and lovastatin (nmol/g dry feces/d)
Bile acids Neutral Sterols
Group C LC DC CDC UDC Total BA COP-ol COP-3-one CHOL erol CHOL anol Total NS
Control 15.0 14.3 10.7 5.1 1.7 46.7 11.5 ND 7.2 18.4 37.1
Lovastatin 15.0 12.8 11.6 6.2 1.6 47.1 12.0 ND 6.7 18.9 37.6
Gl (2.5%) 16.9 16.2 14.3 8.5a 1.9 57.8a 11.7 4.2a 7.7 16.9 40.6
Gl (5%) 12.2 13.9 12.0 6.4 1.4 45.8 12.0 7.8a 7.0 14.1a 41.0
Feces were collected quantitatively at the conclusion of the experiment (D18). C, cholate; LC, lithocholate; DC, deoxycholate; CDC, 
chenodeoxycholate, UDC, Ursodeoxycholate; COP, coprostan; CHOL, cholest; BA, bile acids; NS, neutral sterols. ND, not detected. Values 
represent mean of 6 determinations. aSignificantly different from the control (P < 0.05), students unpaired, 2-tailed t-test, equal variances. No 
statistical trends (P < 0.10) existed in the data set.
Table 5: HMG-CoA reductase activity in hamster hepatic microsomes (pmol [14C]mevalonolactone/min/mg microsomal protein)
Group Activity-NaF Total activity+NaF
Control 12.36 9.30
Lovastatin 13.34 ND
Gl (2.5%) 5.86a 2.66a
Gl (5%) 8.08a 4.86a
Refer to the text for methodologic details. [14C]mevalonate was converted to [14C]mevalonolactone with 10 M HCl before the TLC step. Values 
above were corrected for recovery (15–63%) with [3H]mevalonate. G. lucidum, but not lovastatin, was found to inhibit ex vivo synthesis whether: 
recovery was accounted for; results were expressed per gram liver weight; [14C]mevalonolactone was first extracted into organic solvent and then 
applied to TLC plates [79] rather than applying aqueous extracts directly to TLC plates [55] as reported above (data not shown); and whether or 
not endogenous phosphatase activity was inhibited with 50 mM NaF (shown above). Values represent mean of 6 determinations. aSignificantly 
different from control, students unpaired, 2-tailed t-test, equal variances (P < 0.05). ND, not determined.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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There were no significant differences in TAG and VLDL
with  Gl  or lovastatin (Table 6). VLDL was however a
minor lipoprotein pool. Lovastatin had not significant
effects on LDL nor HDL; Gl decreased LDL 26% and HDL
16% (P < 0.01; D14 vs 29). Gl did not affect statistically
significantly affect LDL/HDL since both individual
parameters decreased from D14-29.
Fecal bile acids and neutral sterols in minipigs
The high cholesterol-fat diet decreased chenodeoxycho-
late; and increased coprostanol, coprostan 3-one, and
cholesterol from D1-14 (P < 0.05 or < 0.10; Table 7). Gl
trended to increase cholestanol (D14 vs 29; P < 0.10).
Discussion
Active components in Gl and in vitro activity
As described, lovastatin was not detected in our Gl mush-
room preparations. By contrast, statin-like compounds
have been found in oyster mushrooms [47] and Chrysospo-
rium pannorum [48].
We did however detect oxygenated lanosterol molecules
such as 32-methyl- and 26-oxo sterols, ganoderols-A and
B, Y ganoderic acid, and ganoderals-A and B in the organic
layer. The organic layer strongly inhibited cholesterol bio-
synthesis from acetate. Similar or identical oxygenated
lanosteroids had been previously reported in Gl [38-42],
and found to inhibit conversion of 24,25-dihydrolanos-
terol to cholesterol at the lanosterol 14 α-demethylase
step [49-51], and also indirectly to inhibit HMG-CoA
reductase activity [51]. The fact that the aqueous phase
from Gl was ineffective at inhibiting cholesterol synthesis
(ID50 > 330) suggests that hydrophilic molecules such as
glucans and fibers in Gl do not affect conversion of acetate
to cholesterol. Such molecules may however affect choles-
terol absorption and bile acid recycling.
Ex vivo hepatic HMG-CoA reductase and fractional 
cholesterol synthesis rate in hamsters
The observed inhibition of ex-vivo HMG-CoA reductase
activity in hamsters treated with Gl  has similarly been
observed with Gl in rats [51], and with pure lanosterol
analogs [44,52]. Our lack of effect with lovastatin (4.3
µmol/kg body wt) contrasts results with the related statin,
simvastatin, where 10, 30, and 60 µmol/kg body wt/d
increased ex-vivo hepatic HMG-CoA reductase activity 2-,
Table 6: Plasma cholesterol and triacylglycerol in minipigs treated with G. lucidum and lovastatin (mmol/L)
Group TC TC TC TC TAG TAG TAG TAG VLDL VLDL LDL LDL HDL HDL LDL/HDL LDL/HDL
D1 D14 D21 D29 D1 D14 D21 D29 D14 D29 D14 D29 D14 D29 D14 D29
Gl (2.5%) 2.47a 3.21bc 2.81 2.58 0.53 0.57 0.80 0.69 0.07 0.09 1.45c 1.08 1.69c 1.42 0.88 0.79
Lovastatin 2.36a 3.00 2.44 2.81 0.50 0.60 0.59 0.71 0.10 0.09 1.40 1.29 1.50 1.43 0.95 0.91
Lovastatin was administered at 80 mg/d. Between D1-14, all pigs received a high cholesterol and fat control diet; from D15-29, pigs received either 
G. lucidum (Gl) extract or lovastatin. The same statistical conclusions were reached if all 10 pigs were compared between D1-14. Pigs were 
randomly selected to receive either GI or lovastatin before study commencement. Student's, paired, 1-tailed, t-test, was utilized for statistical 
comparisons. Statistically significant changes (P < 0.05, 1-tailed testing) in cholesterol parameters are indicated as follows: aD1 vs. 14; bD14 vs. 21; 
cD14 vs. 29. Abbreviations: refer to Table 3. There was a slight trend for 2.5% Gl to reduce LDL/HDL ratio between D14-29 (P < 0.11, 1-tailed 
testing).
Table 7: Fecal bile acids and neutral sterols in minipigs treated with G. lucidum and lovastatin (nmol/g dry feces)
Bile acids Neutral Sterols
Group NCT C CDC COP-ol COP-3-one CHOL erol CHOL anol
All pigs (D1) 1.98 0.86 0.66a 2.41a 0.10a 1.73a* 0.96
All pigs (D14) 1.98 1.33 0.16 3.75 0.17 2.96 0.91
Gl (D14) 1.98 1.61 0.14 3.61 0.18 3.37 0.87b*
Gl (D29) 1.98 0.81 0.16 4.44 0.15 3.15 1.22
Lovastatin (D14) 1.98 0.99 0.19 3.92 0.15 2.44 0.96
Lovastatin (D29) 1.98 1.23 0.18 3.28 0.16 2.34 1.14
Feces were collected on D1, 14 and 29. A quantitative fecal collection was not possible, hence results are expressed per gram of feces. 
Abbreviations: refer to Table 4, except, NCT, 23- Nor β cholanate 5α,7α,12α triol. A paired, 2-tailed students t-test, equal variances, evaluated 
effects of the high cholesterol and fat diet, between D1-14 (10 minipigs); and the effects of Gl or lovastatin between D15-29 (5 minipigs/group), 
indicated as follows: aD1 vs 14, for all minipigs combined (P < 0.001).bD14 vs 29 (P < 0.05). *0.05 < P < 0.1, to indicate statistical trends.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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17-, and 50-fold, respectively [53]. Lovastatin could have
different effects on HMG-CoA reductase and other
enzymes than simvastatin, and was not however exam-
ined in the above study.
Lanosterol analogs such as those found in Gl are known
to inhibit translation of HMG-CoA reductase mRNA, and
may also accelerate protein degradation [44,52]. Gl may
also affect cholesterol biosynthesis at latter biosynthetic
steps such as the conversion of lanosterol [51], which
could in turn, indirectly inhibit HMG-CoA reductase
activity, as reported for statins in minipigs [53]. Indeed, it
was reported that repression of the lanosterol 14 α-
demethylase step can result in accumulation of 3 β-
hydroxy-lanost-8-en-32-al, a known translational down-
regulator of HMG-CoA reductase [54].
If Gl had direct physical effects on HMG-CoA reductase
activity, this implies that even after the 16 h fast employed
in hamsters, Gl  components were still bound to the
enzyme during the assay procedure [55]. After the 16 h
fast, lovastatin could have been removed from the enzyme
accounting for the lack of observed effects of lovastatin on
ex-vivo HMG-CoA reductase activity. Due to removal of
the drug, other statins have even been found to increase
ex-vivo HMG-CoA reductase activity [56]. Hepatic ex-vivo
HMG-CoA reductase activity and whole body cholesterol
FSR are entirely different types of measurements. It is not
clear why Gl and lovastatin did not influence cholesterol
FSR in hamsters. In principle, the low saturated fat-choles-
terol condition employed via use of a chow diet, should
have led to a high endogenous rate of cholesterol synthe-
sis, one that could be inhibited by Gl and lovastatin. It is
conceivable that the Gl  and lovastatin became decom-
posed in the dietary mixture. To test this hypothesis, we
re-extracted Gl and lovastatin from stored diets after cul-
mination of the experiments, and found no differences in
bioactive components analyzed, compared to the original
starting materials (before addition to the diets; data not
shown).
Cholesterol and triacylglycerol in hamsters and minipigs
Hamsters were fed a low-cholesterol chow-based diet with
no added exogenous cholesterol or saturated fat. Under
these conditions, there was not sufficient cholesterol to
redistribute cholesterol from the HDL to LDL pool [29].
This is why in hamsters, 5% Gl and lovastatin reduced
D18 TC and HDL, but not LDL [57,58].
Using the same types of diet, lovastatin was similarly
found to preferentially reduce HDL in hamsters; and only
when dietary saturated fat was added, were both LDL and
HDL reduced [57].
Another factor contributing to the lack of strong effects in
hamsters, and the total lack of effect in minipigs may be
that the dose of lovastatin was insufficient. In hamsters,
the employed dose of 2 mg lovastatin/100 g diet is ca. 4.3
µmol lovastatin/kg body wt. Himber et al. [57] treated
hamsters with 25 µmol lovastatin/kg body wt, which low-
ered HDL; or 50 µmol, which lowered LDL and HDL [57].
Morand et al. [53] found that 20–200 µmol simvastatin/
kg body wt was sufficient to reduce LDL. Ma et al. [59]
reduced lipoproteins in hamsters with 100 mg lovastatin/
100 g diet. In minipigs, we utilized a dose of 80 mg lovas-
tatin/minipig/d, which may also have been on the low
side. A dose of 24–42 mg was sufficient to lower lipopro-
teins in Hyde Park minipigs [60]. Nevertheless, our partic-
ular species, strain, and location of minipigs may have
responded less aggressively to lovastatin (M. Huff, Per-
sonal Communication, December 2000). In Göttingen
minipigs, a dose of 80 mg simvastatin lowered LDL,
whereas 240 mg lowered LDL and HDL [53]; simvastatin
is likely more effective in minipigs than lovastatin at a
similar dietary weight percent [61,62].
The reduction in TAG with Gl was likely due to lower D1
TAG values in the Gl  groups relative to control. TAG
reductions in hamster models typically occur under con-
ditions of higher saturated fat intake [6,63]. In the only
other peer-reviewed study examining cholesterol lowering
properties of Gl in a small animal model, 5 dietary wt%
dried Reishi mushroom powder was found to decrease TC
in SHR rats; effects on VLDL, LDL and HDL were not stud-
ied [2]. In minipigs, with the high fat-cholesterol feeding
conditions employed, a Gl-induced inhibition of choles-
terol synthesis should result in less availability of hepatic
cholesterol for lipoprotein synthesis. In turn, this has the
potential effect of reducing plasma VLDL cholesterol
secretion, reducing LDL direct secretion; and possibly
reducing VLDL-LDL conversion [64,65]. In the present
work, we did not observe differences in TAG or VLDL in
pigs fed either Gl or lovastatin, however this effect could
have been missed since the VLDL pool represented only a
small lipoprotein pool and/or there was efficient VLDL-
LDL conversion. The reductions in both LDL and HDL
with  Gl is consistent with that seen with higher statin
doses [53].
Fecal bile acids and neutral sterols in hamsters and 
minipigs
In hamsters, Gl increased fecal total bile acids and cheno-
deoxycholate, whereas both doses, increased coprostanol
3-one; the 5% dose decreased cholestanol for unclear rea-
sons. An increase in fecal chenodeoxycholate likely indi-
cates production or recycling of chenodeoxycholate was
enhanced.Lipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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Plasma levels of cholestanol are positively associated with
cholesterol absorption [66]; whereas decreased fecal
cholestanol may indicate plasma cholestanol was
increased and cholesterol absorption was enhanced. In
minipigs,  Gl  tended to increase fecal cholestanol, the
opposite pattern to that of hamsters fed 5% Gl. Coprosta-
nol and coprostanol 3-one are the bacterial products of
cholesterol, which are increased when fecal cholesterol is
increased, or when gut flora are altered [67]. Since fecal
cholesterol and coprostanol levels were not changed by
either dose of Gl, it is not obvious why coprostanol 3-one
accumulated.
Bile salts are now known to possess many different func-
tions acting as detergents, activators of protein kinase C
and phosphatidylinositol-3 kinase; and being important
gene regulators [68,69]. Chenodeoxycholate, deoxycho-
late, and their glycine and taurine conjugates can lead to
farnesoid X receptor/retinoid X receptor (FXR/RXR)-
induced activation of intestinal bile acid binding protein
transcription (I-BABP), and suppression of CYP7α RNA
and protein levels (FXR prevents liver X receptor (LXRα)-
induced transactivation of CYP7α). CYP7α regulates the
committed step in classical bile acid synthesis. Overall, an
increased fecal level of chenodeoxycholate would mean
less chenodeoxycholate is available to activate FXR. Less
activation of FXR would lead to less bile acid recycling and
less inhibition of bile acid synthesis, more hepatic choles-
terol converted to bile acids, and a lowering of plasma
cholesterol.
Overall, it is likely that fibrous and/or lipophilic sterol-
like molecules in Gl altered the absorption and recycling
of bile acids and neutral sterols, leading to altered fecal
accumulation. Monitoring plasma levels of neutral sterols
and bile acids, and quantifying conjugated and de-conju-
gated bile acids, should help to clarify the potential
importance of the observed trends.
Comparing in vitro, ex vivo, and in vivo results
In the present work, the in vitro experiments were per-
formed with fractionated Gl extracts, whereas the ex-vivo
and  in vivo work utilized intact Gl. Intact Gl  contains
fibrous components, which may have affected bile acid
and neutral sterol absorption and recycling. Fibrous com-
ponents could also impair the uptake of lipophilic com-
ponents, such as those inhibiting in vitro cholesterol
synthesis. An additional complexity is that lipophilic
components such as ergostane sterols [39] could also
affect bile acid and neutral sterol levels. Thus, it is difficult
to directly compare our in vitro and in vivo results. Feeding
fractionated and intact mushrooms should help to
unravel the in vivo bioactive components, as has been
accomplished for oyster mushrooms [70].
Conclusions and key findings
In summary, GI was found to have cholesterol lowering
potential in vitro, ex-vitro, and in two animal models, with
some differences between the two animal models. It is
possible that oxygenated lanosterol derivatives in Gl
(partly characterized in the present work) contributed to
this cholesterol lowering by decreasing cholesterol syn-
thesis (changes in in vitro and ex-vivo, but not whole body,
cholesterol synthesis were apparent in the present work).
Fibrous components and glucans in Gl were likely respon-
sible for the observed alterations in fecal neutral sterols
and bile acids in both animal species, ultimately affecting
cholesterol absorption and bile acid recycling and con-
tributing to cholesterol lowering. Next steps are to exam-
ine the cholesterol lowering properties of various doses of
intact and fractionated, chemically characterized, Gl com-
ponents in a placebo-controlled clinical trial. Animal
experimentation should also utilize fractionated materi-
als, and ideally, elucidate mechanisms of action of each
bioactive component. Positive cholesterol-lowering
results in such studies will pave the way for adding Gl to
new cholesterol-lowering foods and medicines, alone,
and in combination with other established cholesterol-
lowering ingredients and drugs.
Materials and methods
Materials
Gl was from Fermenta SA, Payerne, Switzerland. Mush-
rooms were cultivated on a defined formula of sawdust,
wheat straw and millet grain. Substrate was sterilized at
90°C for 48 h, then incubated with Gl seed material from
Mycotec Sàrl (Cernier, Neuchâtel). Cultivation was with
controlled temperature, light, humidity and carbon diox-
ide concentration. Human hepatic T9A4 cells [71] were
grown in LCM serum-free media under 3.5% CO2  at
37°C. Lovastatin was purchased as 20 mg Mevacor tablets
(MSD Chibropharm GmbH, Haar, Germany). HMG-CoA
reductase, DL-3-Glutaryl-3- [14C]-HMG-CoA (2216 MBq/
mmol), R-[5-3H] mevalonic acid ammonium salt (1443
MBq/mmol), and [1-14C] acetic acid sodium salt (2070
MBq/mmol) were from Amersham (Upsala, Sweden). α-
3-HMG-CoA (cold) and liquid scintillation cocktail were
from Sigma (Buchs, Switzerland). LCM cell medium was
from Biofluids (Rockville, MD). 5β-cholesteane-3α-ol, 5-
α-cholestane and 2,3-nor-5β-cholanicacid-3α,7α,12α-
triol were from Steraloids, Inc. (Newport, Rhode Island);
other steroid standards were from Sigma, and Calbiochem
(La Jolla, California). Methanolic HCl and Sylon HTP
were from Supelco (Buchs, Switzerland). The Cobas Bio
autosampler was from Hoffmann-La Roche (Basel, Swit-
zerland) and reagents were from Roche Diagnostics
(Rotkreuz, Switzerland). Total Cholesterol Kit 352 and
Triacylglycerol Kit 336 were from Sigma. Deuterium was
from Cambridge Isotope Laboratories (Andover, MA). Zn
catalyst was from Biochemical laboratories (UniversityLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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Bloomington, IN). Silica gel thin layer chromatography
(TLC) plates were from Merck Eurolab (Dietikon, Switzer-
land). Coomassie Plus-200 protein assay reagents and
bovine serum albumin fraction V were from Pierce (Rock-
ford, Illinois). All other chemicals were from Sigma.
Preparation of Gl for in vitro testing
Fruiting bodies from Gl (20 g) were dried, milled and
macerated in 0.4 L MeOH/H2O (4:1, v/v) at room temper-
ature for 3d. The mixture was then filtered, evaporated, re-
dissolved in H2O, acidified to pH 3 with 3 M HCl,
extracted 3 × with 150 mL ethyl acetate, and the organic
phase evaporated under vacuum at 30°C, re-dissolved in
10 mL MeOH, and dried with Na2SO4, for HPLC analyses
and in vitro testing.
Chemical analysis of Gl
The presence of lovastatin in Gl was determined by HPLC
with a Nucleosil 100-5 C18 column (250 × 4 mm; Mach-
erey-Nagel, Oensingen, Switzerland) and a Lichrospher
100 RP-18 post column (Merck, Glattbrugg, Switzerland).
Solvent A was H3PO4/H2O (1:2000, by vol); solvent B was
acetonitrile. Separation was initiated with a linear gradi-
ent of 95% A, 5% B, reaching 50% A, 50% B in 45 min,
30% A, 70% B in 46 min, 10% A, 90% B in 48 min, and
0% A, 100% B in 50 min; the run was continued isocrati-
cally 4 min. Initial conditions were maintained 6 min for
re-equilibration; the flow rate was 1 mL/min. The detector
was a G1315 A, series 1100 detector (Hewlett Packard,
Meyrin, Switzerland); absorbance was measured at 254
nm. After selective extraction and purification with differ-
ent adsorbents and solvents, ganoderols and ganoderic
acids were detected by mass spectroscopy and NMR
(details to be published separately).
In vitro activity of Gl extracts
Human hepatic T9A4 cells were grown in LCM serum-free
media under 3.5% CO2 at 37°C. Cells were seeded in 24-
well plates and at confluence, incubated with 1 mM 14C-
acetate (1 mCi/mmol) for 20 h ± mushroom extracts. Lip-
ids were extracted from cells by incubating 2 × with 1.5
mL hexane/isopropanol (3:2, by vol) for 30 min at room
temperature. Combined organic extracts were dried under
N2, re-dissolved in hexane, and separated by TLC with
hexane/diethyl ether/acetic acid (75:25:1, by vol). Choles-
terol synthesis was determined by measuring incorpora-
tion of 14C from acetate to cholesterol. Radioactivity was
assessed with an instant imager and expressed as percent
of control.
Administration of Gl and lovastatin to hamsters
Male Golden Syrian hamsters (Harlan, UK), 3–4 wks, 40–
60 g, were housed individually in Macrolon Type 3 cages
with 12 h alternating periods of light and darkness. Dur-
ing 3 wks preceding treatment, hamsters were fed Nafag
924 hamster complete diet (# 3132/20, Eberle Nafag AG,
Gossau, Switzerland; Table 1). Following body weight
randomization, groups consisted of 6 hamsters/group
receiving either: Nafag diet (control), Nafag mixed with 2
mg lovastatin /100 g diet (powdered in liquid N2); or
Nafag mixed with 2.5 or 5.0% dried Gl. Hamsters were fed
experimental diets for 17 d. Lovastatin is an inhibitor of
HMG-CoA reductase [72], and was used as a positive con-
trol. Dietary intake was recorded daily, body weights
weekly. Feces were collected on D15-18. Hamsters were
injected subcutaneously with 250 µL D2O on D17 and
killed under anesthesia with isoflurane on D18. Follow-
ing a 16 h fast, D1 (0.5 mL) and D18 blood (>3 mL) were
obtained from the retro-orbital cavity and cardiac vein,
respectively, and transferred to EDTA tubes. Plasma was
prepared by centrifugation at 1500 g, 15 min, at 4°C.
Plasma, and hepatic and cecum tissues were stored at -
80°C. Animal procedures were authorized by Service
Vétérinaire du Canton de Vaud, Switzerland, protocol
1247.
Administration of Gl and lovastatin to minipigs
Nine female and one male Göttingen minipig(s) (Jörg
Farm in Bern Switzerland; Minipig-Primärzucht, Auswill,
Switzerland) aged 6–12 mo (18–20 kg), with white (7)
and black (3 minipigs) colorations, were housed in a 30
m2 box with normal light/dark cycle, and kept at room
temperature. Females were chosen because they have
fewer age-related lipid modifications and higher lipid
concentrations than males [73]. One male was acciden-
tally provided in the delivery, however its total cholesterol
(TC), lipoproteins, bile acids and neutral sterols were sim-
ilar to that of other minipigs. Minipigs were randomly dis-
tributed by weight into two separately housed groups,
marked with a plastic label in the ear, and fed twice daily
for 11 d with powdered commercial pig chow (Diet 574,
Minipig-Primärzucht). During a subsequent 4 d adapta-
tion period, minipigs were fed an acclimatization mixture
of chow and increasing amounts of powdered
hypercholesterolemic control diet (custom diet 2604,
Kliba, Kaiseraugst, Switzerland; Table 2) from 0% to
100%, in steps of 25%, designed after Burnett et al.
[64,74], that was consistent with Göttingen minipig nutri-
tional needs [75]. During the following 2 wks (D15-29),
groups were fed control hypercholesterolemic diet pre-
mixed with 2.5% Gl extract; or hypercholesterolemic diet
plus 80 mg lovastatin/pig/d (in four 20 mg tablets) [53],
hand fed to each minipig, mornings, in half an apple. For
acclimatization, on D12-14, minipigs received a half
apple without lovastatin. The study was blinded in that
the diets were coded, and the mushroom extract was
referred to as "Nestlé Special Fiber." Food intake was 3.5%
of body wt/d (based on group average wt), readjusted
weekly, to provide sufficient, but not excessive, calories
[64,65,75]. Diets were distributed at 0700 and 15h00, andLipids in Health and Disease 2004, 3 http://www.lipidworld.com/content/3/1/2
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spread linearly on a clean cement surface to facilitate indi-
vidual consummation. Distilled water was provided ad
libitum. Toys and human contact were provided to avoid
boredom. Fasting 16 h blood samples (10 mL; 20 mL on
D29) were collected in EDTA tubes on D1, 15, 22, 28, and
29 from anterior vena cava. Plasma was prepared by cen-
trifugation as described for hamsters, and stored at -80°C.
Blood collection began at 0800 following injection of the
intra-muscular relaxant Dormicum® (Hoffmann La Roche,
Basel, Switzerland), then the tranqulizer Stresnil® (Janssen
Pharmaceuticals, Beerse, Belgium). After blood sampling
on D1, 15 and 29, minipigs were isolated for 2 h maxi-
mum for individual fecal collections. Some minipigs did
not defecate during this period, whereas others defecated
again following return to their groups. Hence, the morn-
ing fecal collection was qualitative. Feces were stored at -
40°C under N2. Body weight was recorded weekly, and
food intake recorded each morning. Minipigs were
donated to the University of Geneva at the study's conclu-
sion. Animal procedures were authorized by Service
Vétérinaire du Canton de Geneve, Switzerland, protocol
1315, authorization 31.1.1014/1719/1.
Cholesterol and triacylglycerol measurements in hamsters 
and minipigs
Plasma total cholesterol and triacylglycerol were meas-
ured using commercial kits and a Roche Cobas Bio
autosampler. Plasma lipoproteins were separated by size-
exclusion HPLC as previously described [63].
Fractional cholesterol synthesis rate measurements in 
hamsters and minipigs
Measurements of water- and cholesterol deuterium
enrichment were performed with a Finnigan Thermoquest
Delta XL plus Isotopic Ratio Mass Spectrometer (Bremen,
Germany) as previously described [76,77]. Fractional syn-
thesis rate (FSR) of free cholesterol was calculated from a
plasma sample collected 24 h after deuterium oxide sub-
cutaneous injection as follows: FSR (in % pool/d) = 100 ×
(cholesterol enrichment/(water enrichment × 0.478)).
Due to technical reasons, there were insufficient values in
the minipig experiments to reach interpretable
conclusions.
Fecal bile acids and neutral sterol measurements in 
hamsters and minipigs
Fecal neutral sterols and bile acids were extracted from
lyopholized feces, deconjugated, derivatized with Sylon
HTP and analyzed by gas chromatography as previously
described with internal standards: 5-α-cholestane for neu-
tral sterols; 2,3-nor-5β-cholanic acid-3α,7α,12α-triol for
bile acids [63].
Hepatic ex-vivo HMG-CoA reductase measurements in 
hamsters
Freshly excised liver (300 mg) was collected after 16 h fast
of hamsters, minced with scissors, and homogenized with
0.4 mL buffer (50 mM KH2PO4, 0.1 M sucrose, 50 mM
KCl, 50 mM NaCl, 30 mM EDTA, and 2 mM dithiothrei-
tol, ± 50 mM NaF) with a Potter-Elvehjem S homogenizer
with 400 rpm/5 strokes, on ice, after Conde et al. [55].
NaF inhibits dephosphorylation of HMG-CoA reductase
by inactivating phosphoprotein phosphatases, yielding
total phosphorylated HMG-CoA reductase activity. After
washing homogenizer with 0.2 mL buffer, homogenate
was centrifuged at 10000 g, 15 min, at 4°C. Supernatant
was decanted, 0.4 mL cold buffer added, and the tube vor-
texed and re-centrifuged. Pooled post-mitochondrial
supernatants were spun in 1.5 mL ultracentrifuge tubes at
150000 rpm, 10 min, at 4°C in a Sorvall Discovery M 150
micro ultracentrifuge (Kendro Laboratory Products SA,
Carouge-Geneva, Switzerland), and microsomal fractions
stored at -80°C. Microsomal protein (200 µg, 10–18 µL)
was pre-incubated 10 min at 37°C in an agitating bath,
then incubated 15 min with 50 µL substrate solution
(buffer plus 90 mM glucose-6-phosphate, 72 mM EDTA,
9 mM NADP, 6.2 nmol cold HMG-CoA (0.12 mM), 1.3
nmol [14C]HMG-CoA (0.0025 MBq), 0.3 IU glucose-6-
phosphate dehydrogenase, and 0.024 MBq [3H]meval-
onic acid as recovery standard). After 15 min, reaction was
terminated with 25 µL 10 M HCL, then incubated 30 min
at 37°C for mevalonate-mevalonolactone conversion.
Following centrifugation at 1000 g, 1 min, at 4°C to
remove denatured protein, supernatant was applied to
activated (1 h, 105°C) TLC plates, developed in fresh ben-
zene-acetone (1:1, by vol), the mevalonolactone region
scraped (based on migration of cold standards and X-ray
film visualization; Rf 0.42–0.5), and radioactivity meas-
ured in 10 mL scintillation cocktail.
Statistics
Differences between groups were tested by unpaired/
paired, one-tailed/two-tailed, student t-tests, equal vari-
ances, as appropriate for different measurements.
Statistical significance was evaluated at P < 0.05 unless
stated otherwise.
List of abbreviations
D, day; FPLC, fast protein liquid chromatography; GC, gas
chromatography; Gl or G. lucidum, Ganoderma lucidum;
HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A;
HPLC, high pressure liquid chromatography; TLC, thin
layer chromatography; TAG, triacylglycerol; TC, total
cholesterol.
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